Abstract
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Data and samples are available for new studies and collaborations.
Participants Data- and samples were collected in two subsets. 1) A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration was recruited from four Dutch Diabetes clinics between June 2016 and March 2021. At baseline and 1- and 2-year follow-up visits, physical assessments were performed, and blood and urine samples were collected. Participants completed questionnaires about diabetes-related problems, quality of life, neuropathy and impaired awareness of hypoglycaemia at baseline and at the last follow-up visit. A subgroup of participants underwent mixed-meal tolerance tests (MMTT) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. 2) A second cross-sectional cohort, aiming to include 200 participants aged ≥18 years with ≥35 years T1D duration, was recruited from 7 centres, collecting measurements and samples plus 5-year retrospective data.
Findings to date Fasting residual C-peptide secretion associated with decreased risk of impaired awareness of hypoglycaemia. Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 minutes and 120 minutes showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed.
Future plans Research groups are invited to consider the use of this data and sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNA’s, metabolomics and gene expression data, combined with glucometrics, anthropometric/clinical data and additional markers of residual beta-cell function.
Strengths
- The Biomarker cohort is a large longitudinal prospective cohort study with three time points, collecting biosamples and clinical data from participants with well-established and long-standing type 1 diabetes (≥5 years).
- A subgroup with detailed clinical data underwent MMTT tests at two timepoints allowing further residual beta-cell marker studies.
- The Biomarker and Long-Term type 1 Diabetes cohorts represent a “real-world” population, also including participants from non-academic/-specialised centres.
Limitations
- Despite the fact that data and biosamples were collected from more than 600 participants, this number may be too low for (sub) stratification of the data (e.g. insulin delivery modality, different treating centres and therapies etc.).
- In the prospective group there was a relatively high dropout rate of 25% after 2 years, largely affected by the Covid-19 outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Juvenile Diabetes Research Foundation (JDRF), grant no. 3‐SRA‐2014‐291‐M‐R, the Dutch Diabetes Research Foundation, project 2015.16.1856, and the Vrienden van Diabeter (Friends of Diabeter) foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project and amendments for additional research and future research questions were approved by the Medical Ethics Review Board of the University Medical Center Groningen (Prospective cohort: METC 2015/493, NL50314.042.15; LTD cohort: METC 2017/412, NL62401.042.17)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
